Tarsus Pharmaceuticals

Tarsus Pharmaceuticals

Pharmaceuticals
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.

$3.9B

Market Cap • 11/17/2026

2016

(10 years)

Founded

2020

(6 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

37,1

P/S

5,7

P/EBITDA

—

P/OCF

77,3

P/FCF

118,9

P/E

—

BVPS

2,1

EPS

—

Market Cap

Market Cap

3,9B

EV

3,6B

EV/Revenue

5,3

EV/EBITDA

-5,2

EV/EBIT

-5,2

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3,5%

Total Yield

-3,5%

Payout

0%

Retained Earnings

-1,1B

Profitability

Gross Margin

93,2%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

16,9%

Capex/Revenue

2,6%

Capex/D&A

600,6%

Capex/OCF

35%

SBC/OCF

133,8%

% PPE

6,2%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

64,5%

CAGR Op. Income 5Y

137,6%

CAGR Net Income 5Y

132%

CAGR OCF 5Y

53,5%

Leverage

N.D./EBITDA

0,3

Debt/Equity

0%

Current Ratio

2

Quick Ratio

1,8

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium